This report provides a detailed overview of bispecific development. The FDA’s recent approval of Rybrevant marked the third US approval of a bispecific. With multiple bispecifics entering late-stage trials, we expect the pace of approvals to accelerate. In this primer, we mention 200+ bispecific assets, highlight key upcoming catalysts, and detail recent bispecific-focused partnerships.
+49 69 5060 675 62
+49 89 2000 393 70